Antenatal drugs affecting vitamin K status of the fetus and the newborn.
Coumarin derivatives and anticonvulsants administered during pregnancy enter the fetal circulation, interfering with the action of vitamin K. Vitamin K plays a crucial part in the gamma-carboxylation of glutamic acid residues of the vitamin K-dependent coagulation factors prothrombin, FVII, FIX, and FX. Other vitamin K-dependent proteins in the coagulation cascade are protein C and protein S. Vitamin K-dependent bone proteins are osteocalcin and gamma-carboxyglutamate matrix protein. Administration of coumarol derivatives results in under carboxylation of the vitamin K-dependent proteins. Anticoagulation therapy with warfarin is followed by an increased risk of embryopathy, which has been shown to be greatest between gestational weeks 6 and 12. Administration of warfarin is also followed by an increased risk both of fetal intraventricular hemorrhage, and of cerebral microbleedings, which may result in microencephaly and mental retardation. Treatment with coumarol derivatives should therefore be avoided during pregnancy, even in pregnant women with artificial heart valves, and replaced by heparin. Hemorrhage in the newborn related to the use of anticonvulsant drugs during pregnancy occurs very early within the first 24 hours, probably due to increased degradation of vitamin K. Transplacental administration of vitamin K has been shown to prevent neonatal hemorrhage induced by maternal anticonvulsant therapy. Prophylactic administration of vitamin K, especially by intramuscular injection, has been reported to be associated with an increased risk of childhood cancer. However, subsequent extensive studies have yielded no evidence of any relationship between prophylactic vitamin K administration and the occurrence of childhood cancer.
Astedt
B
B
Department of Obstetrics and Gynecology, University Hospital, Lund, Sweden.
D000014:Abnormalities, Drug-Induced / Q000209:etiology*; D000925:Anticoagulants / Q000009:adverse effects* / Q000493:pharmacokinetics; D000927:Anticonvulsants / Q000009:adverse effects* / Q000493:pharmacokinetics; D001779:Blood Coagulation Factors / Q000378:metabolism; D002648:Child; D015331:Cohort Studies; D003374:Coumarins / Q000009:adverse effects* / Q000493:pharmacokinetics; D004827:Epilepsy / Q000188:drug therapy; D005260:Female; D005315:Fetal Diseases / Q000139:chemically induced*; D006470:Hemorrhage / Q000139:chemically induced; D006801:Humans; D007231:Infant, Newborn; D008431:Maternal-Fetal Exchange; D009369:Neoplasms / Q000139:chemically induced / Q000453:epidemiology; D011247:Pregnancy; D011248:Pregnancy Complications / Q000188:drug therapy*; D011297:Prenatal Exposure Delayed Effects; D011499:Protein Processing, Post-Translational; D013548:Sweden / Q000453:epidemiology; D013927:Thrombosis / Q000188:drug therapy; D006113:United Kingdom / Q000453:epidemiology; D014812:Vitamin K / Q000009:adverse effects / Q000502:physiology* / Q000627:therapeutic use; D014813:Vitamin K Deficiency / Q000139:chemically induced* / Q000196:embryology / Q000517:prevention & control
D000925:Anticoagulants; D000927:Anticonvulsants; D001779:Blood Coagulation Factors; D003374:Coumarins; D014812:Vitamin K